This study will assess an investigational treatment for patients diagnosed with all three major types of Epidermylosis Bullosa (EB).

The ESSENCE Study is a Phase 3 clinical trial of SD-101, an investigational topical cream being developed by Amicus, together with Scioderm, to treat skin blistering and lesions associated with Epidermylosis Bullosa.

For more information:

 

Clinical Trial Overview

The ESSENCE Study is a Phase 3 clinical trial of SD-101, an investigational topical cream being developed by Amicus, together with Scioderm, to treat skin blistering and lesions associated with EB. The painful symptoms and burden of daily wound care make EB a devastating illness with a significant unmet need among patients and families.

more »

Participant Criteria

The ESSENCE Study is open to patients one month of age and older, who have a documented diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB. Participants must have a wound that meets specific study criteria as assessed by a healthcare professional.

more »

Study Locations

The ESSENCE Study is being conducted at sites in countries around the world, including sites in Europe and the United States. In the United States, the study will be conducted in various states from coast-to-coast. Additional locations are continually being added. Check the website or contact us for more details.

more »

Thank you for contacting Amicus Therapeutics, and for your interest in SD-101, our investigational topical medication under evaluation as a potential treatment for epidermolysis bullosa (EB). ESSENCE, our Phase 3, double-blind, placebo controlled trial has now completed enrollment. The company anticipates having top-line results for this trial during the middle of 2017.

Completing this trial and analyzing the results is important to better understand the effect of SD-101 on healing wounds of people with EB. While there remains much work to do, the closing of enrollment in the trial is a significant step in the drug development process.

We at Amicus know how hopeful the EB community is to learn of the potential for a first treatment for EB. Amicus will proceed to evaluate the results of the emerging data and determine the next steps in the development of this investigational product. If you have any further questions, please e-mail us again at info@ebstudy.com.